Search PubMed⌕ Search

PubMed · 10894025

[Hypercalcemia].

Abstract

Hypercalcemia may develop as a consequence of a disturbance of one or more links within the feedback system of calcium homeostasis. Hypercalcemic diseases may be caused by the parathyroid glands as well as by their dependent end organs, the kidneys, the intestine, the skeleton. Partial parathyroid hormone activity can be produced by many tumour factors in a paraneoplastic way. Hypercalcemia induces the symptoms of the so-called hypercalcemic syndrome which should be familiar to the physician. Hints towards the cause may be the organ manifestation in case of primary hyperparathyroidism, in case of the other causal diseases they may present with typical components of their clinical picture. Diagnostics should start with the differentiation between parathyroid-related hypercalcemia (autonomous, primary hyperparathyroidism and variants) and the broad spectrum of non-parathyroid hypercalcemia, mainly accompanying malignancies. Symptomatic treatment of hypercalcemia often has to start before the definite diagnosis is confirmed. Later on, this merely symptomatic treatment may be replaced by causal treatment, as far as possible. Symptomatic treatment of hypercalcemia may follow the 'diuretic', the 'antiresorptive', or the 'antiabsorptive' way--the 'extractive' way by hemodialysis is the treatment of choice in case of hypercalcemic crisis accompanied by renal insufficiency.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

R Ziegler. 2000. [Hypercalcemia].. https://doi.org/10.1024/0040-5930.57.6.391

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Applications of nuclear medicine in pediatric oncology.

Nuclear medicine is important in the diagnosis, staging, and long-term surveillance of a number of pediatric cancers. Skeletal scintigraphy is used to evaluate primary skeletal cancers, such as osteosarcoma and Ewing sarcoma, and nonskeletal cancers such as neuroblastoma, lymphoma, medulloblastoma, rhabdomyosarcoma, and retinoblastoma. Metaiodobenzylguanidine scintigraphy is valuable in examinations of children with neuroblastoma. The therapeutic response of primary bone and brain tumors can be assessed using Tl-201 and Tc-99m MIBI scintigraphy. Imaging strategies for staging and monitoring the therapeutic response of Hodgkin's lymphoma include Ga-67 citrate scintigraphy. Pediatric oncologic applications of positron emission tomography are being investigated extensively.

Bone Neoplasms↗

July 2001: 58-year-old man with a temporal bone mass.

The July 2001 Case of the Month (COM). A 58-year-old man with right ear hearing loss since childhood presented with a two year history of dizziness and vertigo. Neuroradiological studies showed a large mass arising from the petrous portion of the temporal bone. The lesion was resected and microscopic examination revealed a cholesterol granuloma with a small component of cholesteatoma. It is important to distinguish between cholesterol granuloma and cholesteatoma because of treatment differences. However, these two entities can occasionally be seen together and rare giant variants have been described.

Bone Neoplasms↗